SCHEMBL16629754

SCHEMBL16629754

c1ccc(-c2ccc(N(c3ccc(-c4ccccc4)cc3)c3ccc4c(c3)c3cc(-c5cccc6ccc7cccnc7c56)ccc3n4-c3ccccc3)cc2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.34
ALK Q9UM73 2/20 0.32
FABP1 P07148 1/20 0.32
HTT P42858 3/20 0.31
MMP2 P08253 3/20 0.31
KDM4E B2RXH2 2/20 0.31
TSHR P16473 2/20 0.31
MAPT P10636 2/20 0.31
TP53 P04637 2/20 0.31
GMNN O75496 1/20 0.31
LMNA P02545 1/20 0.31
HSP90AA1 P07900 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
MMP9 P14780 1/20 0.31
ALOX15 P16050 1/20 0.31
NFKB1 P19838 1/20 0.31
MMP8 P22894 1/20 0.31
CCR1 P32246 1/20 0.31
THPO P40225 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16629752 0.90 METAP2 (0.31) METAP2
SCHEMBL21335739 0.88 METAP2 (0.35) METAP2ALKHTTMAPTALDH1A1
SCHEMBL16629744 0.87 METAP2 (0.32) METAP2
SCHEMBL17946125 0.86 ALK (0.36) METAP2ALKFABP1HTTMMP2
SCHEMBL16629733 0.85 KDM4E (0.35) METAP2KDM4ETSHRALDH1A1CYP2C19
SCHEMBL16629631 0.85 KDM4E (0.38) METAP2ALKFABP1HTTMMP2
SCHEMBL16629757 0.84 LMNA (0.40) METAP2FABP1HTTMMP2KDM4E
SCHEMBL16629623 0.84 ALK (0.36) METAP2ALKFABP1HTTMMP2
SCHEMBL16629751 0.84 HTT (0.35) METAP2FABP1HTTMMP2KDM4E
SCHEMBL16629735 0.83 KDM4E (0.35) METAP2KDM4ETSHRALDH1A1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407394-B2 Triarylamine-substituted benzo[H]quinoline-derivatives as materials for electronic devices MERCK PATENT GMBH (DE) 2019-09-10 US disclosed
US-20160214942-A1 TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2016-07-28 US disclosed
US-20160214942-A1 TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2016-07-28 US disclosed
WO-2015049022-A1 TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160214942-A1 TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES KCNQ1, KCNH1, KCNQ2 METAP2 3484/4885ALK 1679/4885FABP1 4848/4885
US-10407394-B2 Triarylamine-substituted benzo[H]quinoline-derivatives as materials for electronic devices KCNQ1, KCNH1, KCNQ2 METAP2 3484/4885ALK 1679/4885FABP1 4848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.